However, despite demonstrating anti-tumour efficacy in a variety of preclinical ovarian cancer models, in a Phase II trial in ovarian cancer patients with high tumour HER2 expression, only 7.3% responded to the treatment (Table 1) [29,99–101]. The gene discussed is ERBB2; the disease is ovarian carcinoma.